Oncoclínicas shares surge 34% ahead of CVM ruling on potential R$ 6.5 billion tender offer

Oncoclínicas shares were suspended after a 34% rally in anticipation of a CVM board decision regarding a mandatory public tender offer (OPA). The dispute involves shareholders Centaurus and Latache, with market sentiment pricing in a favorable ruling for the OPA. The outcome will determine if a R$ 6.5 billion acquisition process proceeds.